Agitation is a common behavioral aspect often associated with bipolar disorder (BPD) and schizophrenia. It often manifests in the form of tension, violence, or even aggression and can occur in both treated and untreated patients. Patients experiencing an agitated episode usually present to the emergency department and are then likely treated with both nonpharmacological and pharmacological interventions (e.g., Eli Lilly’s Zyprexa IM, Pfizer’s Geodon, Galen’s Adasuve) to ameliorate this behavior. Emerging therapies will likely need to demonstrate improved efficacy, safety, and convenience of administration profiles that would influence physicians’ preference for a brand over the generic alternatives currently available to manage this condition.
QUESTIONS ANSWERED
PRODUCT DESCRIPTION
Special Topics uses quantitative primary research to assess evolving trends and market effects in dynamic disease areas. The product examines topics of high interest within an indication, such as delving into reasons driving physicians’ prescribing decisions or assessing physicians’ receptivity to emerging agents to better understand the nuanced dynamics in the indication.
CONTENT HIGHLIGHTS
Geographies: United States
Primary research: 5 interviews with thought-leading psychiatrists Survey of 70 U.S. psychiatrists and 30 emergency department physicians.
Key drugs covered: Current drug classes: atypical (e.g., Pfizer’s Geodon, Eli Lilly’s Zyprexa IM) and typical antipsychotics, and benzodiazepines. Emerging therapies: BioXcel’s BXCL501, Avanir’s AVP-786, Axsome’s AXS-05, and Lundbeck / Otsuka’s brexpiprazole.
Key insights provided: